Havrix (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix is indicated for the prevention of hepatitis A infection in individuals at risk. It is used in a variety of clinical situations to provide protective immunity.

• Routine immunization of adults and children aged 1 year and older.
• Pre‑travel protection for persons traveling to regions with high hepatitis A prevalence.
• Outbreak control in communities or institutions where hepatitis A cases have occurred.
• Post‑exposure prophylaxis for individuals who have been exposed to hepatitis A virus.
• Protection of people with chronic liver disease or clotting factor disorders.

Side effects of Havrix are generally mild and transient, but serious reactions can occur in rare cases.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Headache.
• Fatigue or malaise.
• Muscle aches.
• Nausea.

Serious

• Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, swelling of the face or throat.
• Guillain‑Barré syndrome (rare neurological disorder).
• High fever persisting more than 48 hours.
• Seizures (rare).

Before administering Havrix, certain precautions should be considered to ensure safety.

• Do not vaccinate individuals with a known severe allergy to any vaccine component, including algeldrate.
• Use caution in pregnant or breastfeeding women; discuss potential benefits and risks with a healthcare professional.
• Immunocompromised patients may have a reduced immune response; vaccination should be evaluated on a case‑by‑case basis.
• Defer vaccination in persons with an acute moderate or severe febrile illness until recovery.
• Children under 1 year of age are not approved for this vaccine.
• Ensure the recommended dosing interval is maintained for optimal protection.

Havrix has limited known drug interactions, but certain situations require attention.

Avoid

• Simultaneous administration of other injectable vaccines unless specifically recommended by guidelines.
• Use in individuals who have received a recent blood product that may contain hepatitis A antibodies.

Use with caution

• Patients receiving immunosuppressive therapy, as vaccine efficacy may be reduced.
• Concurrent use of antipyretics or analgesics that could mask fever after vaccination.
• Individuals on long‑term corticosteroid therapy.
• Co‑administration with live vaccines; maintain appropriate interval as advised.